GO
Loading...

Enter multiple symbols separated by commas

Equipment and Services Health Care Equipment and Supplies

More

  • Medtronic to spend $458M on heart valve developer Tuesday, 25 Aug 2015 | 1:07 PM ET

    Medical device maker Medtronic will pay up to $458 million for a privately held company that is developing a heart valve replacement. The Dublin- based company said Tuesday that it will pay $408 million at the closing of its deal for Twelve Inc. and then make another $50 million milestone-based payment. U.S.-traded shares of Medtronic PLC climbed about 2.4...

  • SACRAMENTO, Calif.— California's health insurance exchange is still sluggish when it comes to resolving customer service problems, leaving many people unable to access health care or finalize their tax returns, a consumer advocacy group said Thursday. Covered California has been slow to fix enrollment mistakes entered into its computer system, according to...

  • Aug 19- Medical device maker Boston Scientific Inc said its stent to prevent the blocking of arteries in the legs was approved in the United States, four years after the device was recalled outside the country due to partial or no deployments. Boston Scientific also develops another medical device called Eluvia Stent that uses Innova's technology and is...

  • Aug 19- Medical device maker Boston Scientific Inc said the U.S. Food and Drug Administration approved its device to prevent the block of arteries in the legs which leads to peripheral artery disease.

  • Aug 17- The U.S. Food and Drug Administration said it has issued warning letters to manufacturers of medical scopes linked with recent superbug outbreaks, citing violations found during inspections of facilities in the United States and abroad. The devices, called duodenoscopes, are flexible tubes inserted down the throat in a procedure called endoscopic...

  • NEW YORK, Aug 7- Johnson& Johnson subsidiary Ethicon Endo-Surgery Inc will get a second chance to hold rival surgical instrument maker Covidien Plc liable for allegedly infringing two patents on a specialized ultrasonic scalpel that cuts and seals blood vessels. The U.S. Court of Appeals for the Federal Circuit on Friday said on Friday a lower court should not...

  • NEW YORK, Aug 7- Johnson& Johnson subsidiary Ethicon Endo-Surgery Inc will get a second chance to hold rival surgical instrument maker Covidien Plc liable for allegedly infringing two patents on a specialized ultrasonic device that cuts and seals blood vessels. The U.S. Court of Appeals for the Federal Circuit on Friday said a lower court should not have...

  • COURT OF APPEAL FOR THE FEDERAL CIRCUIT RULES THAT ETHICON ENDO-SURGERY INC SURGICAL DEVICE PATENT IS VALID- DECISION.

  • FEDERAL CIRCUIT SAYS FOUR ETHICON ENDO-SURGERY DESIGN PATENTS ON SURGICAL INSTRUMENTS ARE VALID, BUT COVIDIEN DOES NOT INFRINGE THEM.

  • Aug 6- Medtronic Plc has recalled 6,912 units of loading system of a recently approved heart device after reports of the presence of particulates. All affected systems have been withdrawn from the market, Medtronic spokeswoman Wendy Dougherty told Reuters on Thursday, adding that no affected loading systems had been released commercially in the United...

  • Aug 6- Medtronic Plc will recall 6,912 units of the loading system of a recently approved heart device after reports of the presence of particulates, the U.S. Food and Drug Administration said. Medtronic said it received 8 reports related to the issue out of 7,347 potentially affected units through July 6, but no reports of "adverse patient effects".

  • We want to be seen as a Chinese company: Novo Nordisk CEO

    Lars Rebien Sørensen, CEO of Novo Nordisk, discusses his company's earnings guidance and strong half year growth, as well as its strategy in China.

  • Aug 4- Medical equipment maker Halyard Health Inc reported a 6 percent fall in second-quarter revenue and cut its full-year profit forecast, hurt by lower sales volume in its surgical and infection prevention business and a stronger dollar. Halyard Health, which was spun off from Kimberly-Clark Corp in November, said it expects net sales growth to decline 1-3...

  • Hospira headquarters

    The federal government says health care facilities should stop using Hospira's Symbiq medication infusion pump because its vulnerable to hacking.

  • BOSTON, July 31- The U.S. Food and Drug Administration on Friday advised hospitals not to use Hospira Inc's Symbiq infusion system, saying a security vulnerability could allow cyber attackers to take remote control of the system. Both the FDA and DHS said they know of no cases where such an attack has been launched, but the FDA said in its advisory that it strongly...

  • WASHINGTON, July 29- The U.S. Defense Department on Wednesday awarded a team led by Leidos Holdings Inc a contract valued at up to $4.34 billion to build a new electronic health record system for 9.6 million current and retired military service members. The Pentagon's chief arms buyer, Frank Kendall, said the contract was worth under $9 billion over the next 18...

  • July 28- Edwards Lifesciences Corp on Tuesday raised its full-year profit forecast, citing strong demand for the medical device maker's replacement heart valves that are implanted in a minimally invasive procedure. The company said it now expects full-year earnings, excluding items, of $4.30 to $4.40 a share. Edwards reported quarterly net income of $112.7...

  • TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a cash and stock deal that will turn the Israeli company into one of the world's largest pharmaceutical firms. It also will allow Dublin- based Allergan, the third-largest generic drugmaker in the United States, to focus on branded drugs...

  • UPDATE 1-Bellerophon's heart device fails study Monday, 27 Jul 2015 | 7:31 AM ET

    July 27- Bellerophon Therapeutics Inc said its implantable heart device failed to prevent heart failure in patients in a large study, casting doubts over an approval for the device in Europe. The device, Bioabsorbable Cardiac Matrix, was licensed to Bellerophon by BioLineRx Ltd in 2009.. BioLineRx's U.S.-listed shares fell 18 percent to $1.76 in premarket...

  • Bellerophon's heart device fails study Monday, 27 Jul 2015 | 6:36 AM ET

    July 27- Bellerophon Therapeutics Inc said its implantable heart device failed to prevent heart failure in patients in a large study, casting doubts over an approval for the device in Europe. The device, Bioabsorbable Cardiac Matrix, was tested in 303 patients who had already suffered a heart attack. The device was licensed to Bellerophon by BioLineRx Ltd in...